TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06741189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home monitoring
Description: The key parameters (heart rate, arterial oxygen saturation, weight) will be measured at home using the measurement tools used by the parents, and tele-transmitted at a discontinuous rate, i.e. once a day for 4 weeks, then once a week for 20 weeks. The measurement tools will be given to the family before discharge from the hospital ward. These parameters will be entered into the Exolis platform, in addition to a very brief questionnaire designed to provide information about the child's diet, muscle tone and any medication he or she is taking. taken by the child.~An alert will be automatically generated for the pediatric cardiology team if the data transmitted by the measurement sensors deviates from an individualized standard, defined for each child and/or each care pathway at the multidisciplinary consultation meeting before the child returns home.~The response will be standardized on the basis of a protocol shared by the 4 investigating centers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual medical monitoring
Description: During the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram.~During the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual medical monitoring
Description: During the first 4 weeks: a weekly consultation including a record of intercurrent events (malaise, cyanosis, hyperthermia, eating difficulties), a record of weight and vital constants (oxygen saturation, heart rate), an examination of the sternotomy or thoracotomy scar, a clinical cardiovascular examination, a 12-lead electrocardiogram and a transthoracic echocardiogram.~During the following 20 weeks: a consultation at 1, 3 and 6 months including the same assessment procedures.
Study: NCT06738368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia chrysanthemi
Description: Given IM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Collection
Description: Undergo bone marrow sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given CIV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given CIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study: NCT05387525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin (Klisyri®) 10 mg/g ointment
Description: Participants will apply tirbanibulin 10 mg/g ointment topically for 5 days over 25 cm\^2 of the face or scalp with Actinic Keratosis (AK).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium 3% Gel
Description: Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
Study: NCT05669989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab intravenous (IV)
Description: Route of administration: IV infusion; Pharmaceutical form: Vial
Study: NCT06738368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given CIV
Study: NCT06740708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCALE-NCD
Description: 1. FCHV home visits every three months, including~   * For hypertension i. Blood pressure measurement with digital BP devices ii. Lifestyle counseling iii. Referral if uncontrolled BP (≥140/90 mmHg) for 3 months~  * For type 2 diabetes i. Fasting blood glucose measurement with glucometer ii. Lifestyle counseling focusing on diabetes management iii. Referral if uncontrolled diabetes (≥126mg/dl) for 3 months~  * For current smokers i. Smoking cessation counseling ii. Referral for nicotine replacement therapy if request by participants~2. Mobile phone messages, including~   * Lifestyle modification~  * Conveyed as voice or text messages, depending on participant preference
Study: NCT06738654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-surgery
Description: Breast-conserving surgery for breast cancer using single-port robotic surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional open surgry
Description: Breast-conserving surgery for breast cancer using traditional open surgery.
Study: NCT06738758

Intervention type: DRUG
Intervention: PCSK9 inhibitor
Description: The patient used PCSK9 inhibitor (with or without statins) in the early hospitalization, and patients continually prescribed or stopped PCSK9 inhibitors treatment during the follow-up visit, which depend on physician's clinical decision and patient preference

Intervention type: DRUG
Intervention: Statin+Ezetimibe compound
Description: The patient used statins and ezetimibe in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.

Intervention type: DRUG
Intervention: Statin
Description: The patient used statins in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
Study: NCT06737341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposomes(BL)
Description: 20ml of bupivacaine liposomes (266mg) + 10 ml of bupivacaine 0.75% hydrochloride + 20ml saline for ultrasound guided CMB.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine(B)
Description: 10 ml of 0.75% bupivacaine hydrochloride + 40ml normal saline for ultrasound-guided bilateral costal margin block
Study: NCT06737224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting + Exercise (FAST+EX): fasting + exercise condition
Description: Participants will complete a 48-hour fast. One hour of exercise will be performed on each morning of the fast.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting only (FAST): Non-exercise fasting condition
Description: Participant will complete a 48-hour fast. No structured exercise will be performed during each of the fasting days.
Study: NCT06741332

Intervention type: DEVICE
Intervention: Methinks software
Description: Introduction in the stroke code workflow the Methinks AI software capable of detecting LVO on NCCT and CTA, and ICH on NCCT.
Study: NCT05669989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab (SAR439684)
Description: Route of administration: IV infusion; Pharmaceutical form: Vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Route of administration: Oral or IV infusion; Pharmaceutical form: Tablets/single use vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Route of administration: Oral; Pharmaceutical form: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Route of administration: Oral; Pharmaceutical form: Hard capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab subcutaneous (SC)
Description: Route of administration: SC injection with the investigational isatuximab injector device; Pharmaceutical form: Vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Route of administration: IV infusion; Pharmaceutical form: Vial
Study: NCT06357546

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous urination during the hour before caesarean section.
Description: Patients will be asked to urinate by spontaneous urination in the hour before the cesarean section with a cytobacteriological urine examination (ECBU) carried out. An ultrasound check by Bladderscan of the post-void residue will be carried out as soon as the patient will be installed on the intervention table. In the event of post-void residue of more than 150 ml, favoring urinary infections, the patient will be excluded from the research.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spontaneous urination during the hour before caesarean section.
Description: Patients will be asked to urinate by spontaneous urination in the hour before the cesarean section with a cytobacteriological urine examination (ECBU) carried out. An ultrasound check by Bladderscan of the post-void residue will be carried out as soon as the patient will be installed on the intervention table. In the event of post-void residue of more than 150 ml, favoring urinary infections, the patient will be excluded from the research.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systematic bladder catherization during caesarean section.
Description: After implementation of loco-regional analgesia by spinal anesthesia, the patient will be positioned, with a perineal toilet and installation of a bladder catheter type Foley ch. 16.
Study: NCT05849922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442970
Description: 1 mL extractable volume of 150 mg/mL SAR442970 filled in 2 mL glass vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL extractable volume of placebo filled in 2 mL glass vial
Study: NCT06579001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal spray dexmedetomidine
Description: Nasal spray dexmedetomidine or saline was used 100ug per patient acording to the group assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasal spray dexmedetomidine
Description: Nasal spray dexmedetomidine or saline was used 100ug per patient acording to the group assignment
Study: NCT06579144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efanesoctocog alfa
Description: Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efanesoctocog alfa
Description: Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Study: NCT05569174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: AIN457 300 mg subcutaneously for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AIN457 subcutaneously for 12 weeks
Study: NCT04814446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: Intramuscular injections of 0,5 ml will be administered at M0, M2 and M6

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vaccination
Description: Intramuscular injections of 0,5 ml will be administered at M0, M2 and M6
Study: NCT05993845

Intervention type: OTHER
Intervention: Recording of total hip arthroplasty
Description: We record total hip arthroplasties (THA) of hip surgeons at Balgrist University Hospital (BUH), Kantonsspital Baden (KSB), Kantonsspital Winterthur (KSW). Video \& audio data are stored locally at Balgrist-managed servers (patient-sensitive information removed).~Data includes:~Demographics (year of birth, sex, smoking status, body mass index) Diagnosis Surgery-specific data \& other surgical procedures during recording Standard preoperative Computed tomography of the hip/pelvis Standard pelvis x-rays pre- \& postoperative Standard axial hip x-rays pre- \& postoperative Western Ontario \& McMaster Universities Osteoarthritis Index \& Harris-Hip-Score To ensure the generated Surgical process model(SPM), evaluated using the recordings obtained from surgeries performed at BUH, generally describes the surgical process of THA, we apply our model to surgeries from the KSB and the KSW. There, 3 THAs are recorded and analyzed regarding commonalities and discrepancies in the SPM.
Study: NCT05602623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Optics System (AO)
Description: Subjects will have their higher and lower order aberrations corrected with the AO system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Optics System (AO)
Description: Subjects will have their higher and lower order aberrations corrected with the AO system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Optics System (AO)
Description: Subjects will have their higher and lower order aberrations corrected with the AO system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Optics System (AO)
Description: Subjects will have their higher and lower order aberrations corrected with the AO system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Optics System (AO)
Description: Subjects will have their higher and lower order aberrations corrected with the AO system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Optics System (AO)
Description: Subjects will have their higher and lower order aberrations corrected with the AO system.
Study: NCT06375200

Intervention type: OTHER
Intervention: No intervention
Description: Observational one-time questionnaire study without intervention

Intervention type: OTHER
Intervention: No intervention
Description: Observational one-time questionnaire study without intervention

Intervention type: OTHER
Intervention: No intervention
Description: Observational one-time questionnaire study without intervention

Intervention type: OTHER
Intervention: No intervention
Description: Observational one-time questionnaire study without intervention
Study: NCT06194435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Monitoring of Participant Progress and Well-being via Video Calls
Description: Participants with Rotator Cuff Syndrome undergo remote evaluations via video calls with a physician. On the same day, they receive an asynchronous exercise brochure containing instructions for performing home exercises three times a day. They are also provided with an exercise diary to track their daily exercise sessions. Follow-up assessments and discussions about their condition take place remotely on video calls with the physician on the 7th and 15th days. During the final video call on the 15th day, participants are asked to submit their exercise diaries via WhatsApp for assessment of exercise adherence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face Clinic-based Monitoring of Participant Progress and Well-being
Description: Participants with Rotator Cuff Syndrome undergo in-clinic evaluations by a physician, during which they receive an exercise brochure with instructions for performing home exercises three times a day. They are also given an exercise diary to track their daily exercise sessions. On the 7th and 15th days, participants return for follow-up assessments and discussions about their condition. During the final clinic visit, participants are requested to submit their exercise diaries for assessment of exercise adherence.
Study: NCT06628765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8.6 Fr single-use fURS (XFGC-FU-660RC)
Description: Comparative device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 6.3 Fr single-use fURS (Hugemed, HU30S)
Description: Device being tested
Study: NCT06741332

Intervention type: OTHER
Intervention: Normal CT scans evaluation
Description: The control group is obtained from a historical cohort at each participating center. We include consecutive suspected acute stroke patients who meet the same inclusion/exclusion criteria defined above, except for Methinks image processing.
Study: NCT06738940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Auto-CPAP treatment (AirSense™ 10 Autoset™, ResMed Inc., Australia) for 48 weeks
Study: NCT06739395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet
Description: Usage and dosage: The recommended dosage is 200mg, twice a day, equivalent to a total daily dose of 400mg.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided(from the I-PREDICT study).
Study: NCT05309655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Stress Cardiac Magnetic Resonance Imaging
Description: Adenosine stress CMR test with contrast to include cardiovascular structural and functional measures including myocardial blood flow through quantitative perfusion mapping. Participants will have 3 stress tests as a part of this research. These tests will happen when at the beginning of the study, and then every year for 2 years.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: A 12-lead electrocardiogram will be done when at the start of the study and at the participant's 2 year stress test to look at the electrical signals of your heart.
Study: NCT06121505

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose radiation therapy and stereotactic body radiation therapy
Description: Patients will receive radiation therapy.
Study: NCT05309655

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiogram
Description: Contrasted coronary CT angiography will be performed for visual and quantitative analysis of coronary artery plaque burdens.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Testing
Description: 10 teaspoons of blood will be withdrawn at every visit that participants receive a stress test. Participants may have up to six blood draws associated with each imaging visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Survey
Description: A general health status survey with 10 questions and should take about 5-10 minutes to finish. This survey is related to research.
Study: NCT06223880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: Up to 10 weeks in open-label period;~Up to 26 weeks in double-blind period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Up to 26 weeks in double-blind period
Study: NCT05479643

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Surface Electromyography
Description: Surface ElectroMyoGraphy (SEMG) is a non-invasive technique for measuring muscle electrical activity that occurs during muscle contraction and relaxation cycles. Electrodes will be attached with a AgCl gel to muscles used for articulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Electromyography
Description: Surface ElectroMyoGraphy (SEMG) is a non-invasive technique for measuring muscle electrical activity that occurs during muscle contraction and relaxation cycles. Electrodes will be attached with a AgCl gel to muscles used for articulation.
Study: NCT05861583

Intervention type: OTHER
Intervention: fat tissue
Description: fat tissue sample collected while cosmetical liposuction

Intervention type: OTHER
Intervention: lipoedema tissue (stage 1)
Description: lipoedema tissue sample (stage 1) collected while medical liposuction

Intervention type: OTHER
Intervention: lipoedema tissue (stage 2)
Description: lipoedema tissue sample (stage 2) collected while medical liposuction

Intervention type: OTHER
Intervention: lipoedema tissue (stage 3)
Description: lipoedema tissue sample (stage 3) collected while medical liposuction
Study: NCT06739395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablet
Description: Usage, dosage, and administration method: The recommended dose is 2 mg, taken orally once a day with an interval of approximately 24 hours. The dose should be taken at least 1 hour before meals or 2 hours after meals. Do not take any missed doses of trametinib within 12 hours of taking the next dose.The dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study: NCT06121505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Study: NCT05667649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RB-ADSC
Description: Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)